Protalix BioTherapeutics ... (PLX)
Protalix BioTherapeutics Inc. (PLX) Stock Price, Analysis & Data
| Bid | 2.01 |
| Market Cap | 188.54M |
| Revenue (ttm) | 80.62M |
| Net Income (ttm) | 18.95M |
| Beta | 0.01 |
| EPS (ttm) | 0.23 |
| PE Ratio (ttm) | 10.17 |
| Forward PE | 3.77 |
| P/B (ttm) | 2.81 |
| P/S (ttm) | 2.34 |
| Earnings Date | Aug 14, 2025 |
| Ask | n/a |
| Volume | 237,793 |
| Avg. Volume (20D) | 690,696 |
| Open | 2.30 |
| Previous Close | 2.29 |
| Day's Range | 2.28 - 2.35 |
| 52-Week Range | 1.48 - 3.19 |
| Analyst | Strong Buy |
| Price Target | 11 (370.09%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombina...
Financial Performance
In 2025, Protalix BioTherapeutics's revenue was 52.74M, a decrease of -1.23% compared to the previous year's 53.4M. Earnings were -6.6M, a decrease of -325.24%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for PLX stock is "Strong Buy". The 12-month stock price forecast is 11, which is upside of 370.09% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
